SEC Comment Letter 0000000000-23-003507 to Lexaria Bioscience Corp. (LEXX, LEXXW) (CIK 0001348362) (LEXX)
Lexaria Bioscience Corp. (LEXX, LEXXW) (CIK 0001348362)
Date: April 7, 2023 · CIK: 0001348362 · Accession: 0000000000-23-003507
AI Filing Summary & Sentiment
File numbers found in text: 333-271096
Letter
United States securities and exchange commission logo April 7, 2023 Christopher Bunka Chief Executive Officer Lexaria Bioscience Corp. 100 - 740 McCurdy Road, Kelowna British Columbia, Canada, V1X 2P7 Re:Lexaria Bioscience Corp. Registration Statement on Form S-1 Filed April 3, 2023 File No. 333-271096 Dear Christopher Bunka: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Avital Perlman, Esq.
Show Raw Text
United States securities and exchange commission logo
April 7, 2023
Christopher Bunka
Chief Executive Officer
Lexaria Bioscience Corp.
100 - 740 McCurdy Road, Kelowna
British Columbia, Canada, V1X 2P7
Re:Lexaria Bioscience Corp.
Registration Statement on Form S-1
Filed April 3, 2023
File No. 333-271096
Dear Christopher Bunka:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Avital Perlman, Esq.